Newsroom
Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Corporate Sustainability
  • Careers
Company Announcement
11 June 2025

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the...
Company Announcement
06 June 2025

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs...
Company Announcement
05 June 2025

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Inside information
05 June 2025

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH...
Company Announcement
04 June 2025

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA , AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA,...
Company Announcement
04 June 2025

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane...
Company Announcement
02 June 2025

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
Company Announcement
28 May 2025

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to...
Company Announcement
26 May 2025

Alvotech Annual General Meeting to be held June 25, 2025

The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the premises of Arendt & Medernach at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand...
Managers’ Transactions
23 May 2025

Transactions of Managers and Closely Associated Persons

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition...
1…89…32
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.